Santen Pharmaceutical Co Ltd
TSE:4536
Santen Pharmaceutical Co Ltd
TSE:4536
Price:
1 595
JPY
2.7%
Market Closed
Market Cap:
553.5B
JPY
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Santen Pharmaceutical Co Ltd
1595
+42 (+2.7%)
| 52 Week Range |
1 384.5
1 876.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Santen Pharmaceutical Co Ltd
Income Statement
Earnings Waterfall
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co Ltd
|
Revenue
|
302.6B
JPY
|
|
Cost of Revenue
|
-127.3B
JPY
|
|
Gross Profit
|
175.3B
JPY
|
|
Operating Expenses
|
-137.9B
JPY
|
|
Operating Income
|
37.3B
JPY
|
|
Other Expenses
|
-11.2B
JPY
|
|
Net Income
|
26.1B
JPY
|
Income Statement
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co Ltd
Currency: JPY
| Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||||||||||
| Revenue |
148 917
N/A
|
154 116
+3%
|
161 831
+5%
|
176 119
+9%
|
187 784
+7%
|
194 233
+3%
|
195 291
+1%
|
197 322
+1%
|
195 247
-1%
|
196 754
+1%
|
199 096
+1%
|
205 039
+3%
|
212 042
+3%
|
217 021
+2%
|
224 942
+4%
|
225 476
+0%
|
228 511
+1%
|
229 560
+0%
|
234 026
+2%
|
236 679
+1%
|
238 457
+1%
|
243 142
+2%
|
241 555
-1%
|
239 982
-1%
|
241 685
+1%
|
241 015
0%
|
249 605
+4%
|
257 028
+3%
|
259 459
+1%
|
263 620
+2%
|
266 257
+1%
|
266 804
+0%
|
266 413
0%
|
270 242
+1%
|
279 037
+3%
|
285 893
+2%
|
295 928
+4%
|
302 084
+2%
|
301 965
0%
|
304 347
+1%
|
302 563
-1%
|
|
| Gross Profit | ||||||||||||||||||||||||||||||||||||||||||
| Cost of Revenue |
(56 780)
|
(56 212)
|
(56 373)
|
(60 654)
|
(66 287)
|
(71 674)
|
(72 829)
|
(73 355)
|
(73 164)
|
(73 731)
|
(74 966)
|
(78 152)
|
(81 101)
|
(83 483)
|
(86 378)
|
(87 819)
|
(89 179)
|
(90 042)
|
(90 764)
|
(91 862)
|
(93 294)
|
(95 307)
|
(94 831)
|
(95 452)
|
(96 234)
|
(96 371)
|
(98 221)
|
(100 404)
|
(101 383)
|
(105 028)
|
(109 671)
|
(111 153)
|
(112 706)
|
(112 417)
|
(112 950)
|
(114 569)
|
(116 504)
|
(119 101)
|
(123 256)
|
(125 237)
|
(127 308)
|
|
| Gross Profit |
92 137
N/A
|
97 904
+6%
|
105 458
+8%
|
115 465
+9%
|
121 497
+5%
|
122 559
+1%
|
122 462
0%
|
123 967
+1%
|
122 083
-2%
|
123 023
+1%
|
124 130
+1%
|
126 887
+2%
|
130 941
+3%
|
133 538
+2%
|
138 564
+4%
|
137 657
-1%
|
139 332
+1%
|
139 518
+0%
|
143 262
+3%
|
144 817
+1%
|
145 163
+0%
|
147 835
+2%
|
146 724
-1%
|
144 530
-1%
|
145 451
+1%
|
144 644
-1%
|
151 384
+5%
|
156 624
+3%
|
158 076
+1%
|
158 592
+0%
|
156 586
-1%
|
155 651
-1%
|
153 707
-1%
|
157 825
+3%
|
166 087
+5%
|
171 324
+3%
|
179 424
+5%
|
182 983
+2%
|
178 709
-2%
|
179 110
+0%
|
175 255
-2%
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(61 541)
|
(64 699)
|
(70 084)
|
(75 177)
|
(34 973)
|
(38 757)
|
(42 282)
|
(43 775)
|
(88 501)
|
(89 776)
|
(91 651)
|
(93 163)
|
(96 210)
|
(98 460)
|
(99 762)
|
(101 006)
|
(100 855)
|
(97 257)
|
(101 872)
|
(100 489)
|
(101 878)
|
(107 451)
|
(106 864)
|
(112 224)
|
(112 241)
|
(113 146)
|
(113 828)
|
(143 297)
|
(145 769)
|
(146 929)
|
(120 609)
|
(120 587)
|
(155 647)
|
(158 466)
|
(130 787)
|
(169 997)
|
(136 560)
|
(133 962)
|
(126 019)
|
(140 163)
|
(137 940)
|
|
| Selling, General & Administrative |
(35 207)
|
(37 213)
|
(48 074)
|
(52 030)
|
(54 617)
|
(57 416)
|
(58 382)
|
(60 194)
|
(60 557)
|
(60 922)
|
(62 193)
|
(63 149)
|
(65 131)
|
(67 114)
|
(68 788)
|
(69 905)
|
(70 586)
|
(70 507)
|
(71 273)
|
(71 146)
|
(71 220)
|
(72 884)
|
(73 360)
|
(72 864)
|
(73 180)
|
(73 346)
|
(79 554)
|
(84 450)
|
(85 964)
|
(87 056)
|
(84 499)
|
(83 479)
|
(87 142)
|
(89 677)
|
(96 257)
|
(97 895)
|
(97 135)
|
(95 504)
|
(91 529)
|
(91 842)
|
(90 569)
|
|
| Research & Development |
(12 590)
|
(12 466)
|
(17 477)
|
(17 993)
|
(18 550)
|
(19 294)
|
0
|
(20 560)
|
(21 050)
|
(21 636)
|
(22 786)
|
(23 241)
|
(24 224)
|
(24 752)
|
(24 398)
|
(24 405)
|
(23 621)
|
(23 595)
|
(23 759)
|
(24 315)
|
(24 208)
|
(23 821)
|
(23 341)
|
(22 783)
|
(23 052)
|
0
|
(24 112)
|
(18 087)
|
(18 798)
|
(25 262)
|
(26 377)
|
(27 355)
|
(28 305)
|
(29 256)
|
(28 297)
|
(27 499)
|
(26 490)
|
(24 822)
|
(25 416)
|
(24 618)
|
(23 899)
|
|
| Depreciation & Amortization |
(2 071)
|
(3 374)
|
(4 798)
|
(5 349)
|
(5 681)
|
(5 953)
|
(7 229)
|
(6 359)
|
(6 374)
|
(6 377)
|
(6 412)
|
(6 482)
|
(6 567)
|
(6 647)
|
(6 740)
|
(6 823)
|
(6 889)
|
(6 977)
|
(6 988)
|
(7 726)
|
(8 451)
|
(9 167)
|
(9 898)
|
(9 869)
|
(9 840)
|
(10 230)
|
(10 650)
|
(10 623)
|
(10 559)
|
(10 161)
|
(9 734)
|
(9 867)
|
(10 112)
|
(9 703)
|
(9 518)
|
(9 292)
|
(9 051)
|
(9 375)
|
(9 471)
|
(9 574)
|
(9 276)
|
|
| Other Operating Expenses |
(11 673)
|
(11 646)
|
265
|
195
|
43 875
|
43 906
|
23 329
|
43 338
|
(520)
|
(841)
|
(260)
|
(291)
|
(288)
|
53
|
164
|
127
|
241
|
3 822
|
148
|
2 698
|
2 001
|
(1 579)
|
(265)
|
(6 708)
|
(6 169)
|
(29 570)
|
488
|
(30 137)
|
(30 448)
|
(24 450)
|
1
|
114
|
(30 088)
|
(29 830)
|
3 285
|
(35 311)
|
(3 884)
|
(4 261)
|
397
|
(14 129)
|
(14 196)
|
|
| Operating Income |
30 596
N/A
|
33 205
+9%
|
35 374
+7%
|
40 288
+14%
|
86 524
+115%
|
83 802
-3%
|
80 180
-4%
|
80 192
+0%
|
33 582
-58%
|
33 247
-1%
|
32 479
-2%
|
33 724
+4%
|
34 731
+3%
|
35 078
+1%
|
38 802
+11%
|
36 651
-6%
|
38 477
+5%
|
42 261
+10%
|
41 390
-2%
|
44 328
+7%
|
43 285
-2%
|
40 384
-7%
|
39 860
-1%
|
32 306
-19%
|
33 210
+3%
|
31 498
-5%
|
37 556
+19%
|
13 327
-65%
|
12 307
-8%
|
11 663
-5%
|
35 977
+208%
|
35 064
-3%
|
(1 940)
N/A
|
(641)
+67%
|
35 300
N/A
|
1 327
-96%
|
42 864
+3 130%
|
49 021
+14%
|
52 690
+7%
|
38 947
-26%
|
37 315
-4%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
438
|
(287)
|
489
|
843
|
134
|
215
|
(665)
|
(1 695)
|
(2 567)
|
(4 317)
|
(2 406)
|
(1 840)
|
(871)
|
597
|
747
|
(16)
|
(110)
|
(134)
|
(519)
|
(1 663)
|
(1 549)
|
(706)
|
270
|
(856)
|
(1 172)
|
(1 769)
|
(499)
|
(827)
|
(578)
|
(901)
|
(1 750)
|
457
|
61
|
(1 008)
|
(2 415)
|
(3 331)
|
(3 651)
|
(3 861)
|
(7 217)
|
(8 491)
|
(7 678)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(111)
|
0
|
0
|
0
|
2 250
|
0
|
0
|
0
|
(7 474)
|
0
|
0
|
0
|
(25 361)
|
0
|
0
|
0
|
1 390
|
0
|
0
|
0
|
(38 688)
|
0
|
(1 833)
|
(5 806)
|
(15 027)
|
0
|
0
|
|
| Total Other Income |
(116)
|
(122)
|
0
|
0
|
1
|
0
|
(45)
|
(1)
|
0
|
(1)
|
(18)
|
0
|
0
|
1
|
(177)
|
0
|
(1)
|
(1)
|
(4)
|
(2)
|
0
|
(2)
|
(565)
|
0
|
(2)
|
0
|
(8)
|
0
|
(1)
|
0
|
(1)
|
0
|
0
|
(1)
|
4
|
0
|
0
|
0
|
(572)
|
0
|
1
|
|
| Pre-Tax Income |
30 918
N/A
|
32 796
+6%
|
35 863
+9%
|
41 131
+15%
|
86 659
+111%
|
84 017
-3%
|
79 470
-5%
|
78 496
-1%
|
31 015
-60%
|
28 929
-7%
|
30 055
+4%
|
31 884
+6%
|
33 860
+6%
|
35 676
+5%
|
39 261
+10%
|
36 635
-7%
|
38 366
+5%
|
42 126
+10%
|
43 117
+2%
|
42 663
-1%
|
41 734
-2%
|
39 676
-5%
|
32 091
-19%
|
31 448
-2%
|
32 036
+2%
|
29 727
-7%
|
11 688
-61%
|
12 500
+7%
|
11 728
-6%
|
10 761
-8%
|
35 616
+231%
|
35 519
0%
|
(1 879)
N/A
|
(1 650)
+12%
|
(5 799)
-251%
|
(2 005)
+65%
|
37 378
N/A
|
39 353
+5%
|
29 874
-24%
|
30 456
+2%
|
29 638
-3%
|
|
| Net Income | ||||||||||||||||||||||||||||||||||||||||||
| Tax Provision |
(10 436)
|
(11 190)
|
(11 831)
|
(13 622)
|
(28 729)
|
(27 362)
|
(26 097)
|
(25 342)
|
(8 793)
|
(8 280)
|
(8 331)
|
(8 471)
|
(9 396)
|
(3 767)
|
(4 000)
|
(3 534)
|
(3 974)
|
(10 845)
|
(11 174)
|
(11 182)
|
(11 039)
|
(10 823)
|
(10 377)
|
(10 000)
|
(9 753)
|
(7 464)
|
(2 562)
|
(2 172)
|
(2 046)
|
(3 166)
|
(8 427)
|
(8 961)
|
(7 205)
|
(6 545)
|
(9 184)
|
(9 261)
|
(11 067)
|
(11 668)
|
(3 171)
|
(3 558)
|
(3 506)
|
|
| Income from Continuing Operations |
20 482
|
21 606
|
24 032
|
27 509
|
57 930
|
56 655
|
53 373
|
53 154
|
22 222
|
20 649
|
21 724
|
23 413
|
24 464
|
31 909
|
35 261
|
33 101
|
34 392
|
31 281
|
31 943
|
31 481
|
30 695
|
28 853
|
21 714
|
21 448
|
22 283
|
22 263
|
9 126
|
10 328
|
9 682
|
7 595
|
27 189
|
26 558
|
(9 084)
|
(8 195)
|
(14 983)
|
(11 266)
|
26 311
|
27 685
|
26 703
|
26 898
|
26 132
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
7
|
12
|
18
|
(9)
|
(14)
|
(16)
|
(21)
|
9
|
11
|
17
|
28
|
26
|
1 904
|
1 960
|
1 998
|
2 052
|
185
|
135
|
123
|
67
|
29
|
(18)
|
(46)
|
0
|
35
|
69
|
63
|
44
|
(60)
|
(36)
|
2
|
|
| Net Income (Common) |
20 483
N/A
|
21 605
+5%
|
24 032
+11%
|
27 508
+14%
|
57 930
+111%
|
56 656
-2%
|
53 373
-6%
|
53 155
0%
|
22 221
-58%
|
20 650
-7%
|
21 731
+5%
|
23 426
+8%
|
24 483
+5%
|
31 899
+30%
|
35 247
+10%
|
33 083
-6%
|
34 370
+4%
|
31 290
-9%
|
31 954
+2%
|
31 498
-1%
|
30 723
-2%
|
28 877
-6%
|
23 618
-18%
|
23 406
-1%
|
24 279
+4%
|
24 312
+0%
|
9 307
-62%
|
10 458
+12%
|
9 799
-6%
|
7 655
-22%
|
27 212
+255%
|
26 531
-3%
|
(9 138)
N/A
|
(8 203)
+10%
|
(14 955)
-82%
|
(11 205)
+25%
|
26 365
N/A
|
27 720
+5%
|
26 634
-4%
|
26 851
+1%
|
26 125
-3%
|
|
| EPS (Diluted) |
49.11
N/A
|
52.05
+6%
|
57.93
+11%
|
66.28
+14%
|
139.25
+110%
|
136.19
-2%
|
128.41
-6%
|
127.77
0%
|
53.54
-58%
|
50.48
-6%
|
52.76
+5%
|
57.41
+9%
|
60.02
+5%
|
78.18
+30%
|
86.42
+11%
|
81.09
-6%
|
84.23
+4%
|
76.63
-9%
|
78.44
+2%
|
78.7
+0%
|
76.74
-2%
|
72.12
-6%
|
59.01
-18%
|
58.48
-1%
|
60.65
+4%
|
60.7
+0%
|
23.26
-62%
|
26.11
+12%
|
24.46
-6%
|
19.11
-22%
|
67.97
+256%
|
66.77
-2%
|
-24.05
N/A
|
-21.22
+12%
|
-38.6
-82%
|
-29.96
+22%
|
72.91
N/A
|
78.1
+7%
|
72.34
-7%
|
74.53
+3%
|
74.5
0%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
